Information Provided By: 
Fly News Breaks for December 6, 2016
AGIO
Dec 6, 2016 | 09:13 EDT
Needham analyst Chad Messer views nearly all updates presented by Agios at the American Society of Hematology Annual Meeting as incrementally positive, but notes that shares traded down yesterday over safety concern from a single patient with cholestatic hepatitis on AG-519. However, the analyst believes this view is misguided in light of additional data presented on response by genotype. He reiterates a Buy rating and $60 price target on the shares.
News For AGIO From the Last 2 Days
There are no results for your query AGIO
